Kensington, MD, United States of America

Mark A Hoon

This inventor holds 23 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Taste Receptor Modulation. Top assignees: University of California, The United States of America, as Represented by the Secretary, Department of Health and Human Services, The Government of the United States of America. Active years: 2008-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark A Hoon. Retrieved from https://idiyas.com/inventor/mark-a-hoon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 3)

% Patents Active = 30.4

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 4.6

ph-index = 6

Forward Citations = 246(Granted Patents)

Location History:

Kensington, MA (US) (2011)
Kensington, MD (US) (2008 - 2022)

Company Filing History:

20 out of 16,025

University of California

patents

14 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

1 out of 12

The Government of the United States of America

patents

4. 1 out of 255

The United States of America

patents

5. 1 out of 1

The United States of America as Represented by Nih

patent

where one patent can have more than one assignee

Years Active: 2008-2022

Loading Chart...

Areas of Expertise:

Pruritus Inhibition

Taste Receptors

Natriuretic Polypeptide B

T2R Receptor

Sweet Taste Receptors

Amino Acid Heterodimers

Compounds Modulation

Nucleic Acids Encoding

Taste Transduction

Modulators Screening

Mammalian Receptors

Bitter Taste Receptors

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11324725 - Compositions and methods for the inhibition of pruritus (2022-05-10),

2. 10583173 - Methods of treating or preventing pruritis by blocking natriuretic polypeptide b (2020-03-10),

3. 9987330 - Methods of treating or preventing pruritis by blocking natriuretic polypeptide B (2018-06-05),

4. 9817000 - Method for identifying compounds that modulate a T2R taste receptor (2017-11-14),

5. 9347935 - Mammalian sweet and amino acid heterodimeric taste receptors comprising T1R3 and T1R1 (2016-05-24),

6. 9063124 - Method for identifying compounds that modulate a T2R taste receptor (2015-06-23),

7. 8624012 - Nucleic acids encoding T2R bitter taste receptors (2014-01-07),

8. 8580527 - Methods for identifying compounds which modulate T2R bitter taste receptors (2013-11-12),

9. 8470970 - Mammalian sweet and amino acid heterodimeric taste receptors comprising T1R3 and T1R1 (2013-06-25),

10. 8329885 - Nucleic acid encoding a T2R taste receptor (2012-12-11),

11. 8198048 - Mammalian sweet taste receptors (2012-06-12),

12. 7977060 - Mammalian sweet taste receptors (2011-07-12),

13. 7888045 - Methods for identifying modulators of SF taste receptor signaling (2011-02-15),

14. 7868150 - Nucleic acids encoding T2R taste receptors (2011-01-11),

15. 7842786 - Mammalian sweet and amino acid heterodimeric taste receptors comprising T1R3 and T1R1 (2010-11-30),

Title: Mark A. Hoon: Innovator in Pruritus Treatment and Molecular Inhibition

Introduction

Mark A. Hoon, based in Kensington, MD, is a prominent inventor recognized for his significant contributions to the field of pharmaceutical compositions and treatment methods. With a remarkable portfolio of 23 patents, Hoon has dedicated his research and innovation to enhancing health outcomes, particularly in the management of pruritus.

Latest Patents

Among his latest inventions, Hoon has developed compositions and methods for the inhibition of pruritus. One of his notable patents discloses pharmaceutical compositions that comprise a molecular inhibitor of Npr1, which are pivotal in treating, reducing, or preventing both acute and chronic pruritus in mammals. Another significant invention focuses on methods for treating or preventing pruritis by blocking natriuretic polypeptide B (Nppb). This patent outlines the use of Nppb blocking agents administered in effective amounts to alleviate pruritis, alongside a promising in vitro method for identifying compounds that inhibit Nppb activity.

Career Highlights

Mark A. Hoon's career includes noteworthy associations with esteemed institutions such as the University of California and the United States of America as represented by the Department of Health and Human Services. His academic and professional journey is marked by an unwavering commitment to advancing pharmaceutical science and improving therapeutic strategies.

Collaborations

Throughout his career, Hoon has collaborated with respected colleagues in the field, including Charles S. Zuker and Jon Elliot Adler. These partnerships have fostered innovative research and laid the groundwork for advancements in the treatment of pruritus and related conditions.

Conclusion

Mark A. Hoon stands as a distinguished inventor whose work has made significant strides in the medical field. His innovative patents and collaborations reflect a dedication to addressing challenging health issues, particularly in the domain of pruritus treatment. As his career progresses, Hoon’s contributions are sure to leave a lasting impact on pharmaceutical sciences and patient care.

Profile summary based on public USPTO records.